- Home
- ERIE vs RPRX Comparison
ERIE vs RPRX Comparison
Compare ERIE & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERIE
- RPRX
- Stock Information
- Founded
- ERIE 1925
- RPRX 1996
- Country
- ERIE United States
- RPRX United States
- Employees
- ERIE N/A
- RPRX N/A
- Industry
- ERIE Specialty Insurers
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- ERIE Finance
- RPRX Health Care
- Exchange
- ERIE Nasdaq
- RPRX Nasdaq
- Market Cap
- ERIE 19.2B
- RPRX 15.6B
- IPO Year
- ERIE 1995
- RPRX 2020
- Fundamental
- Price
- ERIE $319.41
- RPRX $36.03
- Analyst Decision
- ERIE
- RPRX Strong Buy
- Analyst Count
- ERIE 0
- RPRX 4
- Target Price
- ERIE N/A
- RPRX $44.50
- AVG Volume (30 Days)
- ERIE 125.7K
- RPRX 5.2M
- Earning Date
- ERIE 10-30-2025
- RPRX 11-05-2025
- Dividend Yield
- ERIE 1.71%
- RPRX 2.44%
- EPS Growth
- ERIE 17.80
- RPRX 54.86
- EPS
- ERIE 11.95
- RPRX 2.32
- Revenue
- ERIE $3,973,472,000.00
- RPRX $2,305,243,000.00
- Revenue This Year
- ERIE $10.96
- RPRX $35.14
- Revenue Next Year
- ERIE $8.12
- RPRX $1.24
- P/E Ratio
- ERIE $26.73
- RPRX $15.51
- Revenue Growth
- ERIE 12.00
- RPRX 3.02
- 52 Week Low
- ERIE $306.80
- RPRX $24.05
- 52 Week High
- ERIE $541.64
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- ERIE 43.63
- RPRX 51.05
- Support Level
- ERIE $313.73
- RPRX $35.36
- Resistance Level
- ERIE $322.54
- RPRX $36.67
- Average True Range (ATR)
- ERIE 5.87
- RPRX 0.74
- MACD
- ERIE 1.40
- RPRX 0.08
- Stochastic Oscillator
- ERIE 76.83
- RPRX 68.36
About ERIE Erie Indemnity Company
Erie Indemnity Co mainly performs services on behalf of the Erie Insurance Exchange relating to sales, underwriting, and issuance of policies. Erie Indemnity's results are tied to the performance of the Insurance Exchange, which principally provides automobile and homeowners insurance for individuals, along with multiperil, workers' compensation, and commercial automobile insurance for its commercial clients. The company operates exclusively in the United States.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.